Triveni Bio is a biotech company founded in 2019 and based in the United States. The company is pioneering a genetics-informed precision medicine approach to develop functional antibodies for the treatment of I&I disorders. Their innovative approach establishes proof-of-concept at the earliest stages of drug development, leveraging a strong understanding of genetics and mechanistic biology to power their pipeline for indication expansion. The last notable milestone for Triveni Bio was a $92.00M Series A investment on 26 October 2023, with participation from leading investors including Atlas Venture, Polaris Partners, OrbiMed, Invus, Alexandria Venture Investments, Cormorant Asset Management, and Viking Global Investors. For more information, visit www.triveni.bio.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $92.00M | 7 |
|
26 Oct 2023 |
No recent news or press coverage available for Triveni Bio.
We care about your data, and we'd love to use cookies make your experience better.
